Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Komal L JhaveriCarlos Henrique Dos AnjosTony TaldoneRui WangElizabeth ComenMonica FornierJacqueline F BrombergWeining MaSujata PatilAnna RodinaNaga Vara Kishore PillarsettySusan DugganSarhe KhoshiNathan KadijaGabriela ChiosisMark P DunphyShanu ModiPublished in: JCO precision oncology (2020)
The combination of PU-H71 and nab-paclitaxel was well tolerated, with evidence of clinical activity. More durable disease control without progression was observed in patients with high baseline epichaperome expression. A phase II trial of this combination with PU-PET as a companion diagnostic for patient selection is currently planned.